These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12189183)

  • 1. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in B6C3F(1)/Tk+/- mice treated neonatally with zidovudine and lamivudine.
    Von Tungeln LS; Hamilton LP; Dobrovolsky VN; Bishop ME; Shaddock JG; Heflich RH; Beland FA
    Carcinogenesis; 2002 Sep; 23(9):1427-32. PubMed ID: 12189183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine.
    Von Tungeln LS; Dobrovolsky VN; Bishop ME; Shaddock JG; Heflich RH; Beland FA
    Mutagenesis; 2004 Jul; 19(4):307-11. PubMed ID: 15215330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine.
    Von Tungeln LS; Williams LD; Doerge DR; Shaddock JG; McGarrity LJ; Morris SM; Mittelstaedt RA; Heflich RH; Beland FA
    Environ Mol Mutagen; 2007; 48(3-4):258-69. PubMed ID: 16850453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations.
    Torres SM; Walker DM; Carter MM; Cook DL; McCash CL; Cordova EM; Olivero OA; Poirier MC; Walker VE
    Environ Mol Mutagen; 2007; 48(3-4):224-38. PubMed ID: 17358033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC.
    Dobrovolsky VN; Shaddock JG; Mittelstaedt RA; Bishop ME; Lewis SM; Lee FW; Aidoo A; Leakey JE; Dunnick JK; Heflich RH
    Environ Mol Mutagen; 2007; 48(3-4):270-82. PubMed ID: 17358030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of mutations in the Tk gene of Tk(+/-) mice treated as neonates with 3'-azido-3'-deoxythymidine (AZT).
    Mittelstaedt RA; Von Tungeln LS; Shaddock JG; Dobrovolsky VN; Beland FA; Heflich RH
    Mutat Res; 2004 Mar; 547(1-2):63-9. PubMed ID: 15013700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA adduct formation and induction of micronuclei and mutations in B6C3F1/Tk mice treated neonatally with acrylamide or glycidamide.
    Von Tungeln LS; Churchwell MI; Doerge DR; Shaddock JG; McGarrity LJ; Heflich RH; Gamboa da Costa G; Marques MM; Beland FA
    Int J Cancer; 2009 May; 124(9):2006-15. PubMed ID: 19123476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
    Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
    Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
    Meng Q; Su T; O'Neill JP; Walker VE
    Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of in vivo mutations induced by N-ethyl-N-nitrosourea in the autosomal Tk and the X-linked Hprt genes of mouse lymphocytes.
    Dobrovolsky VN; Chen T; Heflich RH
    Environ Mol Mutagen; 1999; 34(1):30-8. PubMed ID: 10462721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice.
    Venerosi A; Valanzano A; Alleva E; Calamandrei G
    Teratology; 2001 Jan; 63(1):26-37. PubMed ID: 11169552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micronucleated erythrocyte frequency in control and azidothymidine-treated Tk+/+, Tk+/- and Tk-/- mice.
    Dobrovolsky VN; McGarrity LJ; VonTungeln LS; Mittelstaedt RA; Morris SM; Beland FA; Heflich RH
    Mutat Res; 2005 Mar; 570(2):227-35. PubMed ID: 15708581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.
    Chan SS; Santos JH; Meyer JN; Mandavilli BS; Cook DL; McCash CL; Kissling GE; Nyska A; Foley JF; van Houten B; Copeland WC; Walker VE; Witt KL; Bishop JB
    Environ Mol Mutagen; 2007; 48(3-4):190-200. PubMed ID: 16395692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pms2 deficiency results in increased mutation in the Hprt gene but not the Tk gene of Tk(+/-) transgenic mice.
    Dobrovolsky VN; McKinzie PB; Shaddock JG; Mittelstaedt RA; Heflich RH; Parsons BL
    Mutagenesis; 2003 Jul; 18(4):365-70. PubMed ID: 12840110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3'-azido-3'-deoxythymidine.
    Meng Q; Su T; Olivero OA; Poirier MC; Shi X; Ding X; Walker VE
    Toxicol Sci; 2000 Apr; 54(2):322-9. PubMed ID: 10774814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3'-azido-3'-deoxythymidine induces deletions in L5178Y mouse lymphoma cells.
    Wang J; Chen T; Honma M; Chen L; Moore MM
    Environ Mol Mutagen; 2007; 48(3-4):248-57. PubMed ID: 17358034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
    Girouard M; Diallo K; Marchand B; McCormick S; Götte M
    J Biol Chem; 2003 Sep; 278(36):34403-10. PubMed ID: 12819190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine.
    Kemp SD; Shi C; Bloor S; Harrigan PR; Mellors JW; Larder BA
    J Virol; 1998 Jun; 72(6):5093-8. PubMed ID: 9573280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver.
    Desai VG; Lee T; Delongchamp RR; Leakey JE; Lewis SM; Lee F; Moland CL; Branham WS; Fuscoe JC
    Mitochondrion; 2008 Mar; 8(2):181-95. PubMed ID: 18313992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.